What molecular imaging of cancer patients can teach us about COVID-19

COVID-19 pandemic had a great impact on health systems and cancer care worldwide. Patients with cancer who develop COVID-19 are at high risk of severe outcomes and clarifying the determinants of such vulnerability of cancer patients would be of great clinical benefit. While the mechanisms of SARS-CoV-2 infection have been elucidated, the pathogenetic pathways leading to severe manifestations of the disease are largely unknown. Critical manifestations of COVID-19 mainly occur in elderly patients and in patients with serious comorbidities including cancer. Efforts to understand the intersection of pathways between severe manifestations of COVID-19 and cancer may shed light on the pathogenesis of critical illness in COVID-19 patients. Here, we will focus our attention on two major fields of potential intersection between COVID-19 and cancer, namely the dysfunction of immune system and the prothrombotic state that can occur in both COVID-19 and cancer patients, testing whether cancer imaging can provide clues to better understand such interactions.

Automated summary

The COVID-19 pandemic has had a significant impact on global health systems and cancer care. Cancer patients who contract COVID-19 are at high risk for severe outcomes, and understanding the determinants of vulnerability in these patients is crucial for clinical benefit. While the mechanisms of SARS-CoV-2 infection have been clarified, the pathways leading to severe manifestations of the disease are still largely unknown. Exploring the intersection between COVID-19 and cancer could provide insights into the pathogenesis of critical illness in COVID-19 patients.